CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CAR T-cells for colorectal cancer immunotherapy: Ready to go?
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞代表了一种新的基因工程化细胞免疫治疗工具,用于对抗癌症。CAR-T 细胞的应用已经彻底改变了血液系统恶性肿瘤的治疗方法。遗憾的是,要将这种治疗开发用于实体瘤(包括结直肠癌),还有很长的路要走。CAR-T 细胞治疗结直肠癌仍处于早期阶段,临床数据稀缺。该疗法的主要局限性包括高毒性、复发以及结直肠癌中CAR-T 细胞治疗难以渗透的肿瘤微环境。在这篇综述中,我们总结了当前的知识,强调了挑战,并讨论了CAR-T 细胞治疗结直肠癌的前景。
Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer.
CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。